Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007301 · ClinicalTrials.gov registry record
Geko™ Cross Therapy Registry - Wound
A clinical trial of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Firstkind.
- Active
- Registry status
- 2,500
- Enrollment target
- 3
- Study locations
NCT05007301 is a study of Diabetic Foot Ulcer and Venous Leg Ulcer that is active but no longer recruiting, run by Firstkind. The registered enrollment target is 2,500 participants, above the 218-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (1047% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT05007301, a study of Diabetic Foot Ulcer and Venous Leg Ulcer, is active but no longer recruiting, sponsored by Firstkind.
- ACTIVE NOT RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 3
- Study locations
Study Summary
The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.
Conditions Studied
Interventions
- DEVICE geko device
Study Locations (3)
Other
- Central London Community Health Care NHS Trust - London
- Norfolk Community Health and Care NHS Trust - Norwich
New York
- Northwell Health System - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007301
The ClinicalTrials.gov registry entry for NCT05007301 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (1047% higher). The listed sponsor is Firstkind, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which geko device is the first listed.
NCT05007301 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT05007301 about?
NCT05007301 is a clinical study titled "Geko™ Cross Therapy Registry - Wound". The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.
What is the current status of trial NCT05007301?
This trial is currently active not recruiting. The enrollment target is 2,500 participants. The study started on 2022-04-04. Estimated completion is 2028-03.
What conditions does trial NCT05007301 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Wound, Arterial Leg Ulcer.
What interventions are being tested in trial NCT05007301?
The interventions under investigation include: geko device (DEVICE).
Who is sponsoring clinical trial NCT05007301?
This trial is sponsored by Firstkind, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05007301 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
-
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
RECRUITING
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.